|
WO2020249712A1
|
|
Treating iron deficiency in subjects at risk of cardiovascular adverse events
|
|
WO2020144667A1
|
|
Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
|
|
WO2020089227A1
|
|
Treating iron deficiency with ferric carboxymaltose
|
|
AU2018328052A1
|
|
Iron complex compounds for therapeutic use
|
|
AU2016283334A1
|
|
Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
|
|
MX2017005419A
|
|
Treatment or prevention of anaemia in pregnant non-human mammals.
|
|
EP2913054A1
|
|
Iron carbohydrate complex for treatment of restless leg syndrome (rls)
|
|
MX346713B
|
|
A stable iron oligosaccharide compound.
|
|
AU2009342799A1
|
|
A stable iron oligosaccharide compound
|
|
BR0308773A
|
|
Iron dextrin compounds for treatment of iron deficiency anemia
|
|
CZ20004325A3
|
|
Process for preparing compound of iron and dextran
|
|
DK199801526A
|
|
Process for Preparing an Iron Dextran Compound, Iron Dextran Compound Prepared by the Process, Pharmaceutical
|
|
DK172860B1
|
|
Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron man
|
